ni Lolet Abania | December 23, 2021
Binigyan na ng Food and Drug Administration (FDA) ngayong Huwebes ng emergency use authorization (EUA) ang anti-COVID-19 drug na molnupiravir sa ilalim ng brand name na Molnarz.
Ayon kay FDA Director General Eric Domingo, ang nasabing gamot ay gagamitin para sa mga pasyenteng may mild hanggang sa moderate COVID-19.
“This can only be given to adults aged 18 and above, who tested positive for COVID-19 and are at risk of developing severe illness,” ani Domingo sa Laging Handa briefing.
“Molnupiravir is given twice a day for five days, but should be given as soon as possible after diagnosis. And it should be given within the first five days after the onset of symptoms,” dagdag ng opisyal.
Pinapayagan ang EUA para sa legal na adminsitrasyon ng gamot sa bansa, subalit hindi ito pinapayagan para sa commercial selling.
“[The] Molnarz [brand of molnupiravir] was the first one to apply for an EUA and it was able to comply with our required safety, efficacy and quality. With the EUA on molnupirvair, we will not be issuing Compassionate Special Permit anymore,” giit ni Domingo.
“Molnupiravir comes in 200 milligram capsules and should be given during the first five days of COVID-19 symptoms otherwise it will not be useful,” dagdag pa niya.
Paliwanag naman ni Domingo na ang molnupiravir ay hindi maaaring ibigay sa mga buntis, mga indibidwal na gumagamit ng contraceptives at lactating women o nagpapasuso dahil sa kakulangan ng sapat na datos na nagpapakitang ang naturang gamot ay ligtas para sa mga nasabing sector.
Comments